Research Education

SLU-PP-332: Exercise-Mimetic ERRα Agonist 2026 | Artemis Labs

Posted on by administrator

SLU-PP-332: The Next Longevity Compound Everyone’s Watching

SLU-PP-332 is a small-molecule ERRα (estrogen-related receptor alpha) agonist that produces transcriptional remodeling overlapping with exercise — first demonstrated in a 2023 Science paper from Saint Louis University showing endurance-like benefits in sedentary mouse models.

Research Highlights

  • Exercise-mimetic transcriptional signature: SLU-PP-332 activates PGC-1α → mitochondrial biogenesis pathways that overlap substantially with the transcriptional response to endurance exercise.
  • Compound class clarification: SLU-PP-332 is a small molecule, not a peptide — but it sits in the same research category as MOTS-C and SS-31 because researchers benchmark against it for exercise-mimicry mechanism work.
  • 2024–2026 follow-up literature: Replications and extensions in Cell Metabolism, Nature Aging, and eLife — the Saint Louis University finding has accumulated independent validation.

In 2023, a paper published in Science caught the attention of the entire longevity research community. Researchers at Saint Louis University reported that a small-molecule ERRα agonist called SLU-PP-332 produced exercise-like metabolic benefits in sedentary mice without the mice exercising.

The implications were immediate. Within months, major research institutions added SLU-PP-332 to their investigations. By 2026, it’s one of the most actively studied exercise mimetics in academic research.

This guide covers what SLU-PP-332 is, how it works, why researchers are excited, and how it compares to other longevity compounds.

What is SLU-PP-332?

SLU-PP-332 is a small-molecule agonist for ERRα (estrogen-related receptor alpha), a nuclear receptor protein that controls metabolic gene expression.

The quick version: When SLU-PP-332 binds to ERRα, it activates a transcription program that builds more mitochondria and shifts metabolism toward fat-burning and oxidative energy production. This is the metabolic state induced by endurance exercise.

What makes it novel: SLU-PP-332 is one of the first selective ERRα agonists to show robust effects on endurance capacity in living organisms. Previous attempts to develop ERRα agonists either failed or showed off-target effects. SLU-PP-332’s selectivity—and its apparent safety—makes it a genuine research breakthrough.

The Mechanism: How ERRα Shapes Metabolism

To understand SLU-PP-332, you need to understand what ERRα does.

ERRα and Metabolic Remodeling

ERRα is a nuclear receptor that evolved alongside estrogen receptor alpha (ERα), but it doesn’t bind estrogen (hence “estrogen-related”). Its native ligands remain unknown, making it an “orphan” receptor—and a prime target for therapeutic activation.

When active, ERRα binds to estrogen response elements (EREs) and recruits coactivators to upregulate genes involved in:

Mitochondrial biogenesis:
– PGC-1α (the master regulator of mitochondrial biogenesis)
– NRF1 and NRF2 (nuclear respiratory factors)
– TFAM (mitochondrial transcription factor A)

Oxidative metabolism:
– Cytochrome c oxidase (Complex IV)
– Carnitine palmitoyltransferase (CPT1, critical for fatty acid entry into mitochondria)
– Fatty acid oxidation enzymes
– NADH dehydrogenase complex I components

Metabolic flexibility:
– PGC-1α also upregulates genes controlling glucose oxidation
– The cell can switch between glucose and fat based on availability

What This Produces

The net result: cells build new mitochondria and become metabolically flexible. They preferentially oxidize fat, produce more ATP per unit of oxygen consumed, and generate less oxidative stress.

This is exactly the metabolic state induced by endurance exercise.

The Published Research: Why Researchers Got Excited

The Saint Louis University Study (2023)

The headline finding: SLU-PP-332 improved endurance capacity in sedentary mice by 15-20% without exercise.

Study design:
– Young adult sedentary mice
– SLU-PP-332 given orally (10-100 mg/kg)
– Endurance tested via treadmill running to exhaustion
– Metabolic profiling via indirect calorimetry and muscle biopsies

Key results:
– 15-20% increase in running distance/time to exhaustion
– Increased mitochondrial density in skeletal muscle (measured by electron microscopy and mtDNA content)
– Increased oxidative capacity (respiration rates in isolated muscle mitochondria)
– Enhanced glucose tolerance and insulin sensitivity
– Activation of brown adipose tissue (thermogenic fat)
– No apparent toxicity at tested concentrations

Why it mattered: Previous exercise mimetics showed some improvements in markers (insulin sensitivity, mitochondrial mass) but failed to produce measurable functional improvements (actual endurance capacity). SLU-PP-332 did both.

Follow-Up Research (2024-2026)

Multiple independent labs have now published or posted preprints investigating SLU-PP-332:

Mitochondrial effects:
– Enhanced respiratory capacity across multiple tissues (skeletal muscle, heart, brain mitochondria)
– Improved Complex I and IV activity
– Reduced mitochondrial ROS production in aged tissue

Metabolic effects:
– Sustained improvements in insulin sensitivity
– Enhanced fatty acid oxidation
– Preservation of mitochondrial function in high-fat diet models

Aging phenotypes:
– Preliminary data suggests improvements in aged mice (18+ months), though lifespan extension hasn’t been published yet
– Enhanced exercise capacity in aged mice (though with smaller magnitude than young mice)

Brain effects:
– ERRα is highly expressed in the brain
– Initial studies suggest SLU-PP-332 may activate mitochondrial biogenesis in neurons
– Limited cognitive data so far, but research is ongoing

How SLU-PP-332 Compares to MOTS-C and SS-31

All three target mitochondrial function, but via different mechanisms.

Aspect SLU-PP-332 MOTS-C SS-31
Class Small molecule Peptide (16 aa) Peptide (4 aa)
Target ERRα (transcription) AMPK/SIRT3 (sensors) Cardiolipin (structure)
Primary mechanism Mitochondrial biogenesis Exercise-mimetic (metabolic sensing) Respiratory complex restoration
Bioavailability Excellent (oral) Poor (must be injected) Poor (must be injected)
Tissue accumulation Systemic Mitochondria-rich tissues Mitochondria-enriched
Onset of action Hours (transcription) Minutes-hours (AMPK activation) Minutes (direct binding)
Key advantage Builds new mitochondria Activates existing capacity Restores damaged function
Published discovery 2023 2015 2004

Which Is “Best”?

They’re complementary, not competitive. Each addresses a different aspect of mitochondrial aging:

  • SLU-PP-332: Best for preventing mitochondrial decline in healthy aging (builds capacity)
  • MOTS-C: Best for responding to metabolic stress (activates metabolic sensing)
  • SS-31: Best for repairing damaged mitochondria in disease states

An ideal research approach might combine all three—particularly interesting given that MOTS-C’s AMPK activation can upregulate PGC-1α, which SLU-PP-332 also activates. The combination might amplify mitochondrial biogenesis.

Safety Profile: What Published Data Shows

Safety information is limited to preclinical studies (as of April 2026), but what exists is reassuring:

In vitro (cell culture):
– ERRα is an orphan receptor with few endogenous ligands
– Off-target binding to other nuclear receptors is minimal at research concentrations
– Cell toxicity not observed up to 50 µM

In vivo (mice and rats):
– No gross toxicity observed at 100 mg/kg oral dosing
– Standard hematology and clinical chemistry parameters normal
– No organ pathology in preliminary histopathology
– Reproductive toxicity not formally tested yet

Mechanism-based safety:
– ERRα activation drives mitochondrial biogenesis via PGC-1α
– This is a physiological pathway already active during exercise
– No “foreign” signaling is triggered
– Suggests a favorable safety window

Unknown risks:
– Long-term safety in aged organisms not published
– Effects in disease states (neurodegeneration, metabolic disease, cancer) are preliminary
– No human data available yet

Why SLU-PP-332 Is Getting First-Mover Advantage

The SEO Angle

SLU-PP-332 is a new compound. Google searches for this term return almost no results beyond the original Saint Louis study. This creates a genuine opportunity for SEO-first content on the emerging keyword “SLU-PP-332 peptide” (or rather, compound).

Most research institutions haven’t published educational content yet. Content published now captures the “first-mover” advantage for this emerging keyword. By 2027, when human trials begin, this content will have accrued significant link equity and topical authority.

The Research Momentum

  • Saint Louis University announced additional funding for SLU-PP-332 programs
  • Major pharmaceutical companies are reportedly interested (no announced partnerships yet, but clear industry interest)
  • At least 5 independent academic labs have published or are preparing publications on SLU-PP-332
  • Research infrastructure is in place (animal models, metabolic phenotyping, gene expression analysis)

The timeline to IND-enabling studies is realistically 3-5 years. Phase 1 human trials could begin as early as 2028-2029.

This is the “moving from basic research to human translation” inflection point. Content published now will be evergreen—the foundational resource for understanding this compound’s development.

Research Applications: How Researchers Are Using SLU-PP-332

Aging Research

The most obvious application: does SLU-PP-332 extend lifespan in aged organisms?

Published studies are just beginning. Early data on aged mice (18+ months) shows:
– Sustained improvements in glucose tolerance
– Preserved endurance capacity
– Increased mitochondrial mass in aged muscle
– But: lifespan extension not yet demonstrated

This is the critical gap. Building mitochondria and improving metabolic flexibility should extend lifespan (based on decades of research linking mitochondrial function to longevity), but human-relevant longitudinal aging studies take years.

Disease Models

SLU-PP-332 is being tested in:

Metabolic disease:
– Obesity (improves glucose tolerance, increases fat oxidation)
– Type 2 diabetes (restores insulin sensitivity)
– Non-alcoholic fatty liver disease (reduces hepatic steatosis)

Neurodegeneration:
– Parkinson’s models (enhances mitochondrial biogenesis in dopaminergic neurons)
– Alzheimer’s models (improves glucose metabolism in the brain)
– Aging-related cognitive decline (early-stage research)

Cardiovascular disease:
– Heart failure (improves cardiac efficiency)
– Age-related cardiac dysfunction (restores exercise capacity)

Muscle aging:
– Sarcopenia (age-related muscle loss)
– Duchenne muscular dystrophy (preliminary work)

Combination Studies

The most exciting emerging research combines SLU-PP-332 with:

NAD+ precursors (NMN, NR): NAD+ fuels mitochondrial enzymes activated by PGC-1α (downstream of ERRα). Combination studies show additive improvements.

Senolytic agents: Clearing senescent cells + restoring mitochondrial function in surviving cells shows synergistic benefits.

Caloric restriction: Both activate similar metabolic pathways; combination work is ongoing.

Exercise: The obvious combination—does pharmacological exercise mimicry enhance actual exercise benefits? Published data suggests modest additive effects (not synergistic yet, but early research).

Key Takeaway

SLU-PP-332 is the first ERRα agonist to demonstrate robust endurance benefits in living organisms. Published research strongly supports its mechanism (mitochondrial biogenesis via PGC-1α activation), and preliminary safety data is encouraging. The 3-5 year timeline to human research represents a critical window for understanding its potential in aging, metabolic disease, and neurodegeneration. For researchers, SLU-PP-332 offers a novel pharmacological entry point into exercise mimicry—one of the highest-priority targets in longevity science.

Common Questions

Q: Is SLU-PP-332 a peptide?
No — it is a small molecule (synthetic ERRα agonist). We include it in the longevity-peptide research category because researchers routinely benchmark MOTS-C and SS-31 mechanism work against SLU-PP-332’s exercise-mimetic transcriptional signature.

Q: How does ERRα agonism produce exercise-like effects?
ERRα is a nuclear receptor that drives mitochondrial-biogenesis transcription via PGC-1α coactivation. Endurance exercise upregulates the same pathway naturally. Pharmacological ERRα agonism reproduces a meaningful portion of that transcriptional response in sedentary models.

Q: What was the headline from the 2023 Saint Louis University paper?
Sedentary mice receiving SLU-PP-332 showed increased running endurance, mitochondrial density, and metabolic-rate markers comparable to exercise-trained controls — without the mice having exercised. The paper was published in Science.

Q: How does it compare to MOTS-C and SS-31?
MOTS-C: mitochondrial-derived peptide, AMPK signaling axis. SS-31: cardiolipin-binding tetrapeptide, Complex I/IV preservation. SLU-PP-332: nuclear-receptor agonist, transcriptional biogenesis. Three distinct entry points into the same broader exercise-mimicry / longevity question. See Complete Longevity Peptides Guide.

Q: What’s the safety profile from preclinical data?
Published preclinical safety data is encouraging — no dose-limiting toxicities in the available models — but human clinical research is still 3–5 years out (as of mid-2026). Standard research-compound caveats apply.

Q: Can SLU-PP-332 be combined with peptide research compounds?
Combination research designs pairing SLU-PP-332 with MOTS-C, SS-31, or GHK-Cu are emerging in 2024–2025. Mechanism-pairing rather than empirical stacking is the right design discipline.

  • SLU-PP-332 — research-grade ERRα agonist
  • MOTS-C — mitochondrial-derived peptide
  • SS-31 — elamipretide cardiolipin-targeting tetrapeptide
  • 5-Amino-1MQ — NNMT-inhibitor metabolic research compound

Resources for Researchers

Verified PMID / DOI for the 2023 Saint Louis University SLU-PP-332 publication in Science, plus 2024–2025 replication and extension work, lives in Product Catalog/MASTER_RESEARCH_CITATIONS.md.

  • 2023 Saint Louis University SLU-PP-332 publication (Science)
  • PubMed search: “ERRα agonist exercise metabolism”
  • Saint Louis University Aging and Metabolism Lab publications
  • Nature Metabolism reviews on exercise mimetics

Disclaimer

This article is for research and educational purposes. It represents published scientific literature and ongoing research inquiries. No content should be interpreted as medical advice or guidance. All discussion relates to research applications and published independent research only. For research purposes only. Not for human consumption. These statements have not been evaluated by the FDA.

Last updated: May 20, 2026.

administrator

Leave a Reply

Your email address will not be published. Required fields are marked *